Abstract
Metabolic effects of deflazacort vs. methylprednisone were studied in prepubertal patients after kidney transplantation. Thirty-one patients participated: 15 received deflazacort and 16 remained on methylprednisone. The study started at a mean of 2.1 years after transplantation, when patients were randomized to either continue with methylprednisone or switch to deflazacort. Height velocity increased more in the deflazacort than in the methylprednisone group only during the first 2 years: 5.4 ± 0.5 vs. 3.5 ± 0.3 cm/year, and 4.2 ± 0.8 vs. 2.2 ± 0.4 cm/year p = 0.007, [by two-way analysis of variance (ANOVA)]. After 2 and 3 years, the number of patients who were overweight increased in the methylprednisone group and decreased in the deflazacort group; p < 0.01. Lean body mass increased more in the deflazacort than in the methylprednisone group (p = 0.003). Fat body mass increased only in the methylprednisone group (p < 0.01). Total cholesterol and low-density-lipoprotein (LDL) cholesterol increased in the methylprednisone group (p < 0.05 and p < 0.01, respectively). Total and LDL cholesterol were reduced (p < 0.01 and p < 0.001, respectively), whereas high-density-lipoprotein (HDL) cholesterol increased (p < 0.001) during deflazacort therapy. Lumbar spine bone mineral density (BMD) decreased in both groups, but total skeleton BMD decreased only in the methylprednisone group (p < 0.001). Finally, normal glucose/insulin ratio, defined as > 7, was associated (p < 0.05) with the deflazacort group. Our data suggest that deflazacort therapy might improve linear growth and lean body mass and prevent excessive bone loss and fat accumulation. It also leads to an improvement in lipoprotein profile without reduction in insulin sensitivity.
Similar content being viewed by others
References
Scudeletti M, Castagneta L, Imbimbo B, Puppo F, Pierri I, Indiveri F (1990) New glucocorticoids. Mechanism of immunological activity at cellular level in the clinical setting. Ann N Y Acad Sci 595:368–382
Markham A, Bryson HM (1995) Deflazacort. A review of its pharmacological properties and therapeutic efficacy. Drugs 50:317–333
Nathanson G, Pasqualucci GR, Redaelli P, Schiatti P, Selva D, Winters G (1969) Steroids possessing nitrogen atoms. V. Some pharmacological and physicochemical aspects of a new class of active corticoids (17α, 16α-d) oxazolino steroids. Steroids 13:365–381
Vignolo M, Milani S, Imbimbo B, Naselli A, Di Battista E, Piaggio G, Leveratto L, Morreale G, Sardella ML, Corsini M, Cerbello G, Barotto M, Benso L, Aicardi G (1991) Statural growth and skeletal maturation in rheumatic prepubertal children treated with a third generation glucocorticoid (Deflazacort) versus prednisone-An interim study. Clin Exp Rheumat 9(Suppl 6):41–45
Pagano G, Lombardi A, Ferraris GM, Imbimbo B, Cavallo-Perin P (1982) Acute effect of prednisone and deflazacort on glucose tolerance in prediabetic subjects. Eur J Clin Pharmacol 22:469–471
Bruno A, Cavallo-Perin P, Cassader M, Pagano G (1987) Deflazacort vs Prednisone: effect on blood glucose control in insulin-treated diabetics. Arch Intern Med 147:679–680
Aicardi G, Milani S, Imbimbo B, Vignolo M, Di Battista E, Gusmano R, Terragna A, Cordone G, Cottafava F, Coppo R, Sernia O, Porcellini MG, Sardella ML, Barotto M, Benso L (1991) Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: an interin long-term analysis. Calcif Tissue Int 48:283–287
Ferraris JR, Faisntein-Day P, Gutman R, Granillo E, Ramirez J, Ruiz S, Pasqualini T (1992) Effect of therapy with a new glucocorticoids, deflazacort, on linear growth and growth hormone secretion after renal transplantation. J Pediatr 121:809–813
Ferraris JR, Pennisi P, Pasqualini T, Jasper H (1997) Effects of deflazacort immunosuppression on long-term growth and growth factors after renal transplantation. Pediatr Nephrol 11:322–324
Ferraris JR, Tambutti ML, Redal M, Ramirez JA, Carlin MC, Samaniego MC, Prigoshin N (1996) Immunosuppressive activity of deflazacort in pediatric renal transplantation. Transplantation 62:417–420
Ferraris JR, Sorroche P, Legal S, Oyhamburu J, Brandi P, Pasqualini T (1998) Effect of therapy with deflazacort on dyslipoproteinemia after pediatric renal transplantation. J Pediatr 133:533–536
Ferraris JR, Pasqualini T, Legal S, Sorroche P, Galich AM, Pennisi P, Domenech H, Jasper H, the Deflazacort Study Group (2000) Effect of deflazacort versus methylprednisone on growth, body composition, lipid profile, and bone mass after renal transplantation. Pediatr Nephrol 14:682–688
Assandri A, Buniva G, Martinelli E, Perazzi A, Zerelli L (1984) Pharmacokinetics and metabolism of deflazacort in the rat, dog, monkey and mean. Adv Exp Med Biol 71:9–23
Legarraga H, Anigstein C, Di Candia A, Heinrich J, Krupitzky S, Machado O, Moreno H (2001) Guías para la evaluación del crecimiento, 2° edición. Sociedad Argentina de Pediatría, Buenos Aires, pp 19–113
Cole TJ, Bellizi MC, Flegal KM, Dietz WT (2000) Establishing a standard definition for children overweight and obesity worldwide: international survey. BMJ 320:1240–1243
Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499–502
Vuguin P, Saenger P, Dimartino-Nardi J (2001) Fasting glucose insulin ratio: a useful measure of insulin resistance in girls with premature adrenache. J Clin Endocrinol Metab 86:4615–4617
Elli A, Rivolta R, Di Palo FQ, Parenti M, Vergallo G, Palazzi P, Zafiropulu S, Abelli C, Zanussi (1993) A randomized trial of deflazacort versus 6-methylprednisolone in renal transplantation immunosuppressive activity and side effects. Transplantation 5:205–212
Fine R (1993) Corticosteroids and growth. Kidney Int 44(Suppl 43):S-59–S-63
Ferraris J, Pasqualini T, Gutman R, Ramirez J, Faisntein-Day P (1997) Growth hormone-insulin like growth factor-I (IGF-I) axis in prepubertal children with chronic renal failure. J Pediatr Endocrinol Metab 10:19–25
Coirini H, Flores D, Vega CM, Gonzalez Deviselle ML, De Nicola AF (1994) Binding of the anti-inflammatory steroid deflazacort to glucocorticoid receptors in brain and peripheral tissues. In vivo A-D in vitro studies. J Steroids Biochem Molec Biol 49:43–49
Reaven GM (1988) Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 37:1595–1607
Lippuner K, Casez JP, Horber FF, Jaeger P (1998) Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: a randomized, double blind study in kidney transplant patients. J Clin Endocrinol Metab 83:3795–3802
Scharer K, Feneberg R, Klaus G, Paschen C, Wuster C, Mehls O, Schaefer F (2000) Experience with deflazacort in children and adolescents after renal transplantation. Pediatr Nephrol 14:457–463
Guerrero R, de la Piedra C, Texeiro E, Bragado R, Traba ML (2004) Hydrocortisone and deflazacort induce different effects on Vitamin D receptor level increase produced by 1,25-dihydroxyvitamin D3 in rat osteoblast-like UMR-106 cells. J Rheumatol 31:167–172
Sarwal M (2006) Steroid elimination is coming of age. Pediatr Nephrol 21:2–4
Marks SD, Trompeter RS (2006) Steroid preservation: the rationale to continued prescribing. Pediatr Nephrol 21:305–307
Höcker B, John U, Plank C, Wühl E, Weber LT, Misselwitz J, Rascher W, Mehls O, Tönshoff B (2004) Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years. Transplantation 78:228–234
Opelz G, Döhler B, Laux G, for the collaborative transplant study (2005) Long-term prospective study of steroid withdrawal in kidney and heart transplant recipients. Am J Transplant 5:720–728
Acknowledgements
We thank Dr. Enrique Soriano and his group (Comité de Investigación Clínica, Hospital Italiano de Buenos Aires), and Verónica Alfonso for secretarial assistance.
Author information
Authors and Affiliations
Consortia
Corresponding author
Additional information
Deflazacort Study Group: José Oyhamburu, José Ramirez (Hospital Italiano); Horacio Repetto, Laila Rodriguez Rilo (Instituto Nefrológico Buenos Aires, Argentina); Amalia Turconi, Norma Delgado (Hospital Garraham, Buenos Aires, Argentina); Ernesto Sojo, María Caletti (Unidad de Nefrología Pediátrica, Buenos Aires, Argentina); Mariana Gutierrez, Patricia Bedecarras (Hospital Ricardo Gutierrez, Buenos Aires, Argentina).
Rights and permissions
About this article
Cite this article
Ferraris, J.R., Pasqualini, T., Alonso, G. et al. Effects of deflazacort vs. methylprednisone: a randomized study in kidney transplant patients. Pediatr Nephrol 22, 734–741 (2007). https://doi.org/10.1007/s00467-006-0403-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-006-0403-0